H.Z. Turna

3.8k total citations · 1 hit paper
8 papers, 367 citations indexed

About

H.Z. Turna is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, H.Z. Turna has authored 8 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in H.Z. Turna's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (3 papers). H.Z. Turna is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (3 papers). H.Z. Turna collaborates with scholars based in Türkiye, Japan and Brazil. H.Z. Turna's co-authors include Dariusz M. Kowalski, Gilberto de Castro, Tony Mok, Byoung Chul Cho, Gilberto Lopes, Yi‐Long Wu, Iveta Kudaba, Igor Bondarenko, Bogusława Karaszewska and К. К. Лактионов and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

H.Z. Turna

8 papers receiving 363 citations

Hit Papers

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
    2022 151 citations Gilberto de Castro, Iveta Kudaba et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H.Z. Turna Türkiye 7 326 264 50 50 48 8 367
M. Souquet-Bressand France 3 315 1.0× 206 0.8× 38 0.8× 56 1.1× 66 1.4× 3 361
M. Grangeon France 2 297 0.9× 188 0.7× 33 0.7× 54 1.1× 51 1.1× 2 330
S. Chaléat France 2 297 0.9× 188 0.7× 33 0.7× 54 1.1× 51 1.1× 2 330
Nicolas Brandone France 5 177 0.5× 155 0.6× 43 0.9× 35 0.7× 59 1.2× 8 249
Farah Louise Lim United Kingdom 4 249 0.8× 159 0.6× 24 0.5× 56 1.1× 25 0.5× 7 287
Paz J. Vellanki United States 7 160 0.5× 115 0.4× 54 1.1× 41 0.8× 57 1.2× 13 254
Grygorii Ursol United Kingdom 4 233 0.7× 143 0.5× 24 0.5× 54 1.1× 27 0.6× 6 268
David Vicente Baz Spain 10 173 0.5× 138 0.5× 29 0.6× 40 0.8× 52 1.1× 27 235
Larry Leon United States 8 258 0.8× 232 0.9× 41 0.8× 25 0.5× 36 0.8× 14 316
Jean Mourlanette France 4 263 0.8× 174 0.7× 164 3.3× 51 1.0× 37 0.8× 4 312

Countries citing papers authored by H.Z. Turna

Since Specialization
Citations

This map shows the geographic impact of H.Z. Turna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.Z. Turna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.Z. Turna more than expected).

Fields of papers citing papers by H.Z. Turna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.Z. Turna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.Z. Turna. The network helps show where H.Z. Turna may publish in the future.

Co-authorship network of co-authors of H.Z. Turna

This figure shows the co-authorship network connecting the top 25 collaborators of H.Z. Turna. A scholar is included among the top collaborators of H.Z. Turna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.Z. Turna. H.Z. Turna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
2.
Castro, Gilberto de, Iveta Kudaba, Yi‐Long Wu, et al.. (2022). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. Journal of Clinical Oncology. 41(11). 1986–1991. 151 indexed citations breakdown →
3.
Cho, Byoung Chul, Yi‐Long Wu, G. Lopes, et al.. (2021). FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC. Journal of Thoracic Oncology. 16(3). S225–S226. 20 indexed citations
4.
Castro, Gilberto de, Iveta Kudaba, Yi‐Long Wu, et al.. (2021). 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer. SHILAP Revista de lepidopterología. A390–A390. 12 indexed citations
5.
Cho, Byoung Chul, Gilberto Lopes, Dariusz M. Kowalski, et al.. (2020). Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC. Cancer Research. 80(16_Supplement). CT084–CT084. 32 indexed citations
6.
Herbst, Roy S., Gilberto Lopes, Dariusz M. Kowalski, et al.. (2019). LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042. Annals of Oncology. 30. xi63–xi64. 79 indexed citations
7.
8.
Turna, H.Z., et al.. (2019). Surgical Management of Breast Cancer in Turkey: a 30-Year Single-Center Retrospective Study of 2531 Patients. Indian Journal of Surgery. 83(1). 28–37. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Souquet-Bressand Breakdown of academic impact, for papers by M. Grangeon Breakdown of academic impact, for papers by S. Chaléat Breakdown of academic impact, for papers by Nicolas Brandone Breakdown of academic impact, for papers by Farah Louise Lim Breakdown of academic impact, for papers by Paz J. Vellanki Breakdown of academic impact, for papers by Grygorii Ursol Breakdown of academic impact, for papers by David Vicente Baz Breakdown of academic impact, for papers by Larry Leon Breakdown of academic impact, for papers by Jean Mourlanette
Rankless by CCL
2026